NCT04307888

Brief Summary

Multicentre prospective registry including consecutive patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in which variables related to the percutaneous access closure for implanting devices at aorta level will be collected and analyzed. The follow-up period will be 30 days after the procedure. The duration of the recruitment period will be one year. All data will be collected telematically and incorporated into a database for subsequent statistical analysis. There will be 2 points for data interim analysis at 6 and 12 months after initiation of the study.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 13, 2020

Completed
19 days until next milestone

Study Start

First participant enrolled

April 1, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

March 23, 2020

Status Verified

March 1, 2020

Enrollment Period

11 months

First QC Date

March 9, 2020

Last Update Submit

March 19, 2020

Conditions

Keywords

Percutaneous access

Outcome Measures

Primary Outcomes (3)

  • Rate of closure-procedure technical success as assessed by absence of femoral pseudoaneurysm or arterial occlusion

    Rate of cases that are reported with a femoral pseudoaneurysm in the site of arterial access or common femoral artery occlusion related to the closure procedure.

    30 days

  • Quality of Life assesed by EuroQol-5 Dimensions (EQ-5D) Questionnaire

    Estimated Impact of the procedure on the Quality of Life measured by EQ-5D Questionnaire on 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. The study participants self-rate their level of severity for each dimension. Rated level can be coded as 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).

    30 days

  • Incidence of Procedure-Emergent Adverse Events related to Frailty as assessed by the Modified Frailty Index (mFI-11)

    Incidence of any postoperative adverse event or mortality related to the frailty assessed by the modified frailty index (mFI-11), an 11-factor score predictive of increased risk for postoperative morbidity and mortality in patients undergoing elective and emergent surgery that scores the frailty between 1 to 11, being the 11 the most frailty status.

    30 days

Secondary Outcomes (3)

  • Time of closure procedure hemostasis in seconds

    1 hour

  • Hospital Stay assessed in days

    30 days

  • Post-operative Pain assessed by the Visual Analog Scale for Pain

    30 days

Study Arms (1)

Study group

Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.

Device: Perclose Proglide (Abbott)

Interventions

Common Femoral Artery percutaneous access closure by means of Perclose Proglide device

Study group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing Percutaneous Endovascular Aneurysm Repair (PEVAR), Percutaneous Endovascular Thoracic Aneurysm Repair (PTEVAR) or Transcatheter Aortic Valve Implantation (TAVI) in who percutaneous access closure device is used for implanting devices at aorta level.

You may qualify if:

  • Men and women over 18 years old
  • Signed informed consent
  • Endovascular procedures on the aorta to any level, performed by percutaneous access and requiring the use of devices ≥ 10F
  • Femoral Access suitable for percutaneous treatment in the opinion of the surgeon

You may not qualify if:

  • Need for surgical repair of the femoral artery (stenosis aneurysmal)
  • Initial indication of percutaneous closure with another device different from the Perclose Proglide
  • Active infection of the puncture site
  • Condition that prevents complete the 30 days follow up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Aortic AneurysmAortic DissectionAortic Valve StenosisAortic CoarctationAortic RuptureAortic Valve Disease

Condition Hierarchy (Ancestors)

AneurysmVascular DiseasesCardiovascular DiseasesAortic DiseasesDissection, Blood VesselAcute Aortic SyndromeHeart Valve DiseasesHeart DiseasesVentricular Outflow ObstructionHeart Defects, CongenitalCardiovascular AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesAneurysm, RupturedRuptureWounds and Injuries

Study Officials

  • Teresa Hernandez Carbonell, MD

    Hospital Quiron Salud Marbella

    STUDY DIRECTOR
  • Francisco J Medina, MD

    Hospital Universitario Burgos

    STUDY DIRECTOR
  • Ignacio Agundez-Gomez, MD

    Hospital Universitario Burgos

    STUDY DIRECTOR

Central Study Contacts

Joaquin De Haro, MD

CONTACT

Francisco J Medina, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
30 Days
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 9, 2020

First Posted

March 13, 2020

Study Start

April 1, 2020

Primary Completion

March 1, 2021

Study Completion

March 1, 2022

Last Updated

March 23, 2020

Record last verified: 2020-03